Qamar Uddin Ahmed, Nur Adlina Mat Nasir, Taslima Begum, A.B.M. Helal Uddin, Humaira Parveen, Mona O. Albalawi, Muhammad Muzaffar Ali Khan Khattak, Syed Najmul Hejaz Azmi, Murni Nazira Sarian, Adelya Desi Kurniawati, Zainul Amiruddin Zakaria
Context: Current treatments for leishmaniasis and Human African Trypanosomiasis (HAT) are constrained by toxicity, high costs, and the growing threat of parasite resistance. In this context, natural products have emerged as promising alternatives, offering the potential for safer and more cost‑effective therapeutic interventions. Objective: This review assesses the antileishmanial and antitrypanosomal activities of medicinal plants, underscoring their significance in addressing parasitic diseases and identifying promising candidates for future drug discovery and development. Methods: Following the PRISMA 2020 guidelines, a systematic search was conducted for literature published between 2003 and 2023. Studies were considered eligible if they reported in vitro activities of extracts or compounds against Leishmania spp. or Trypanosoma brucei with IC50 < 10 µg/mL. Data included plant species, extraction methods, parasite strains, active compound(s), cytotoxicity profiles, and traditional uses. The quality of each study was evaluated based on the reproducibility of experimental procedures. Results and conclusions: A total of fifty eligible articles were included. 217 plants demonstrated potent activity (IC₅。 < 10 µg/mL) against Leishmania spp. and/or T. brucei. Among these, 41 species had documented traditional use in the treatment of leishmaniasis or HAT, whereas 76 were traditionally employed for unrelated ailments yet exhibited scientific evidence of antiparasitic efficacy. Notably, 67 species were active against both parasites, 120 displayed selective antitrypanosomal, and 30 showed selective antileishmanial activities. Exemplary candidates include Achillea ptarmica L. (pellitorine), Allium sativum L. (allicin, ajoene), Strychnos spinosa Lam. (triterpenoids), Tridax procumbens L. (oxylipin), and Marrubium incanum Desr. (salvigenin). More studies should define mechanisms and in vivo efficacy. Systematic review registration: Not registered. © 2026 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.
Drug Discovery and Synthetic Chemistry Research Group, Department of Pharmaceutical Chemistry, Kulliyyah of Pharmacy, International Islamic University Malaysia (IIUM), Pahang, Kuantan, Malaysia; Organic and Medicinal Chemistry Research Lab., Department of Chemistry, Faculty of Science, University of Tabuk, Tabuk, Saudi Arabia; Analytical Chemistry Research Laboratory, Department of Chemistry, Faculty of Science, University of Tabuk, Tabuk, Saudi Arabia; Department of Nutrition Sciences, Kulliyyah of Allied Health Sciences, IIUM, Pahang Darul Makmur, Kuantan, Malaysia; Applied Sciences Department, College of Applied Sciences and Pharmacy, University of Technology and Applied Sciences-Muscat, Muscat, Oman; Institute of Systems Biology (INBIOSIS), Universiti Kebangsaan Malaysia, Selangor, Bangi, Malaysia; Department of Nutrition, Faculty of Health Sciences, Universitas Brawijaya, Puncak Dieng Eksklusif, Kunci, East Jawa, Kabupaten Malang, Indonesia; Borneo Research on Algesia, Inflammation and Neurodegeneration (BRAIN) Group, Faculty of Medicine and Health Sciences, Universiti Malaysia Sabah, Jalan UMS, Sabah, Kota Kinabalu, Malaysia
